Latest & greatest articles for opioid

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on opioid or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on opioid and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for opioid

101. Do ?2-Adrenergic Agonists Decrease the Symptoms Associated With Opioid Withdrawal?

Do ?2-Adrenergic Agonists Decrease the Symptoms Associated With Opioid Withdrawal? DEFINE_ME_WA This site requires Cookies to be enabled to function. Please ensure Cookies are turned on and then re-visit the desired page.

Annals of Emergency Medicine Systematic Review Snapshots2017

102. [Intrathecal opioid infusion pump for chronic cancer and non-cancer pain]

[Intrathecal opioid infusion pump for chronic cancer and non-cancer pain] [Intrathecal opioid infusion pump for chronic cancer and non-cancer pain] [Intrathecal opioid infusion pump for chronic cancer and non-cancer pain] Rey-Ares L, Bardach A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Ciapponi A, López A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been (...) made for the HTA database. Citation Rey-Ares L, Bardach A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Ciapponi A, López A. [Intrathecal opioid infusion pump for chronic cancer and non-cancer pain] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Documentos de Evaluación de Tecnologías Sanitarias, Informe de Respuesta Rapida No 514. 2017 Authors' conclusions Scarce evidence of moderate methodological quality suggests that the use of intrathecal opioids

Health Technology Assessment (HTA) Database.2017

103. Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer

Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer 28445097 2017 04 26 2017 06 07 1527-7755 35 17 2017 Jun 10 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer. 1921-1928 10.1200/JCO (...) .2016.70.8453 Purpose This randomized, double-blind, multicenter study aimed to determine the dose of naldemedine, a peripherally-acting μ-opioid receptor antagonist, for future trials by comparing the efficacy and safety of three doses of naldemedine versus placebo in patients with cancer and opioid-induced constipation. Methods Patients ≥ 18 years old with cancer, an Eastern Cooperative Oncology Group performance status ≤ 2, who had been receiving a stable regimen of opioid analgesics for ≥ 2 weeks, had

EvidenceUpdates2017

104. Abuse-Deterrent Formulations of Opioids: Effectiveness and Value

Abuse-Deterrent Formulations of Opioids: Effectiveness and Value ©Institute for Clinical and Economic Review, 2017 Abuse-Deterrent Formulations of Opioids: Effectiveness and Value Evidence Report June 28, 2017 Prepared for: ©Institute for Clinical and Economic Review, 2017 Page i Evidence Report—Abuse-deterrent Formulations of Opioids: Effectiveness and Value ICER Staff/Consultants Reiner Banken, MD, MSc Senior Fellow Institute for Clinical and Economic Review Foluso Agboola, MBBS, MPH Research (...) Daniel A. Ollendorf, PhD Chief Scientific Officer Institute for Clinical and Economic Review Steven D. Pearson, MD, MSc President Institute for Clinical and Economic Review DATE OF PUBLICATION: June 28, 2017 We would also like to thank Anne Loos, Noah Mwandha, Erin Lawler and Jerry Berger for their contributions to this report.©Institute for Clinical and Economic Review, 2017 Page ii Evidence Report—Abuse-deterrent Formulations of Opioids: Effectiveness and Value About ICER The Institute for Clinical

California Technology Assessment Forum2017

105. The adverse effects of the cytotoxic temsirolimus and the opioid pholcodine

The adverse effects of the cytotoxic temsirolimus and the opioid pholcodine Prescrire IN ENGLISH - Spotlight ''In the July issue of Prescrire International: The adverse effects of the cytotoxic temsirolimus and the opioid pholcodine'', 1 July 2017 {1} {1} {1} | | > > > In the July issue of Prescrire International: The adverse effects of the cytotoxic temsirolimus and the opioid pholcodine Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |  (...)  |   |   |   |   |   |   |  Spotlight In the July issue of Prescrire International: The adverse effects of the cytotoxic temsirolimus and the opioid pholcodine FREE DOWNLOAD In the Adverse Effects section of this issue, the cardiac risks of the cytotoxic immunosuppressant temsirolimus, used in metastatic renal cell carcinoma and mantle cell lymphoma, and the harms caused by the opioid pholcodine, still present in many cough suppressants. Full

Prescrire2017

106. Exploring Patient Characteristics and Barriers to Hepatitis C Treatment in Patients on Opioid Substitution Treatment Attending a Community Based Fibro-scanning Clinic

Exploring Patient Characteristics and Barriers to Hepatitis C Treatment in Patients on Opioid Substitution Treatment Attending a Community Based Fibro-scanning Clinic 28721344 2018 11 13 2450-131X 5 2 2017 Jun Journal of translational internal medicine J Transl Int Med Exploring Patient Characteristics and Barriers to Hepatitis C Treatment in Patients on Opioid Substitution Treatment Attending a Community Based Fibro-scanning Clinic. 112-119 10.1515/jtim-2017-0017 Hepatitis C virus (HCV (...) Germany J Transl Int Med 101673826 2224-4018 blood borne virus drug users fibroscan hepatitis C virus opiate substitution treatments Conflict of Interest All authors declare no conflict of interest. 2017 7 20 6 0 2017 7 20 6 0 2017 7 20 6 1 epublish 28721344 10.1515/jtim-2017-0017 jtim-2017-0017 PMC5506411 J Community Health. 2008 Jun;33(3):126-33 18165889 Int J Drug Policy. 2015 Oct;26(10):893-8 26254497 Eur J Gastroenterol Hepatol. 2010 Mar;22(3):270-7 20425880 Lancet. 2011 Aug 13;378(9791):571-83

Journal of translational internal medicine2017 Full Text: Link to full Text with Trip Pro

107. The Use of Transdermal Buprenorphine Patches in Aiding in Opioid Withdrawal: Clinical Effectiveness and Guidelines

The Use of Transdermal Buprenorphine Patches in Aiding in Opioid Withdrawal: Clinical Effectiveness and Guidelines The Use of Transdermal Buprenorphine Patches in Aiding in Opioid Withdrawal: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need The Use of Transdermal Buprenorphine Patches in Aiding in Opioid Withdrawal: Clinical Effectiveness and Guidelines The Use of Transdermal Buprenorphine Patches in Aiding in Opioid Withdrawal: Clinical Effectiveness (...) and Guidelines Published on: June 8, 2017 Project Number: RA0911-000 Product Line: Research Type: Drug Report Type: Reference List Result type: Report Question What is the clinical effectiveness regarding the use of buprenorphine patches for aiding in opioid withdrawal prior to starting a patient on buprenorphine/naloxone? What are the evidence-based guidelines regarding the use of buprenorphine patches for aiding in opioid withdrawal prior to starting a patient on buprenorphine/naloxone? Key Message One non

Canadian Agency for Drugs and Technologies in Health - Rapid Review2017

109. Progress Report on the Joint Statement of Action to Address the Opioid Crisis in Canada

Progress Report on the Joint Statement of Action to Address the Opioid Crisis in Canada Progress Report on the Joint Statement of Action to Address the Opioid Crisis in Canada MAY 2017 (December 2016 to February 2017)2 Progress Report on the Joint Statement of Action to Address the Opioid Crisis in Canada The Opioid Conference and Summit In recognition that no single individual, approach or organization can effectively “fix” Canada’s opioid crisis alone, the federal Minister of Health Jane (...) Philpott asked the Canadian Centre on Substance Use and Addiction (CCSA) to partner with Health Canada to organize an Opioid Conference and Summit, which was held on November 18 (Conference) and 19 (Summit), 2016. This two-day event, co-hosted by the Honourable Jane Philpott, Federal Minister of Health and the Honourable Eric Hoskins, Ontario Minister of Health and Long-Term Care included a conference on day one followed by a smaller summit on day two. Seven provincial and territorial ministers

Canadian Centre on Substance Abuse2017

110. Postoperative Opioid Prescribing and the Pain Scores on Hospital Consumer Assessment of Healthcare Providers and Systems Survey

Postoperative Opioid Prescribing and the Pain Scores on Hospital Consumer Assessment of Healthcare Providers and Systems Survey 28510669 2017 08 07 2018 11 13 1538-3598 317 19 2017 05 16 JAMA JAMA Postoperative Opioid Prescribing and the Pain Scores on Hospital Consumer Assessment of Healthcare Providers and Systems Survey. 2013-2015 10.1001/jama.2017.2827 Lee Jay S JS Department of Surgery, University of Michigan, Ann Arbor. Hu Hsou M HM Department of Surgery, University of Michigan, Ann Arbor (...) HHS United States R01 DA038261 DA NIDA NIH HHS United States R01 DA038261 DA NIDA NIH HHS United States K23 DA038718 DA NIDA NIH HHS United States P50 AR070600 AR NIAMS NIH HHS United States Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't United States JAMA 7501160 0098-7484 0 Analgesics, Opioid AIM IM Analgesics, Opioid therapeutic use Cardiovascular Surgical Procedures statistics & numerical data Drug Prescriptions statistics & numerical data Female General

JAMA2017 Full Text: Link to full Text with Trip Pro

111. Symproic (naldemedine) Tablets - For the treatment of opioid-induced constipation

Symproic (naldemedine) Tablets - For the treatment of opioid-induced constipation Symproic (naldemedine) Tablets U.S. Department of Health and Human Services Search FDA Submit search Symproic (naldemedine) Tablets Symproic Company: Shionogi Inc. Application No.: 208854 Approval Date: 03/23/2017 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date

FDA - Drug Approval Package2017

112. Randomized, double-blinded, placebo-controlled trial comparing two multimodal opioid-minimizing pain management regimens following transsphenoidal surgery

Randomized, double-blinded, placebo-controlled trial comparing two multimodal opioid-minimizing pain management regimens following transsphenoidal surgery 28298041 2017 03 16 2017 03 16 1933-0693 2017 Mar 03 Journal of neurosurgery J. Neurosurg. Randomized, double-blinded, placebo-controlled trial comparing two multimodal opioid-minimizing pain management regimens following transsphenoidal surgery. 1-8 10.3171/2016.10.JNS161355 OBJECTIVE Pain control is an important clinical consideration (...) and quality-of-care metric. No studies have examined postoperative pain control following transsphenoidal surgery for pituitary lesions. The study goals were to 1) report postoperative pain scores following transsphenoidal surgery, 2) determine if multimodal opioid-minimizing pain regimens yielded satisfactory postoperative pain control, and 3) determine if intravenous (IV) ibuprofen improved postoperative pain scores and reduced opioid use compared with placebo. METHODS This study was a single-center

EvidenceUpdates2017

113. Alternative opioid agonists in the treatment of opioid dependence: a systematic review

Alternative opioid agonists in the treatment of opioid dependence: a systematic review Alternative opioid agonists in the treatment of opioid dependence: a systematic review - NIPH Selected items added to basket Close Vis søkefelt How can we help you today? Search for: Søk Menu • • Alternative opioid agonists in the treatment of opioid dependence: a systematic review Søk i Folkehelsa.no Search for: Søk Infectious diseases & Vaccines Close Mental & Physical health Close Environment & Lifestyle (...) Close Health in Norway Close Quality and Knowledge Close More topics Close Opioid maintenance treatment can help people with opioid dependence to improve their lives. The treatment is effective, but people often experience side effects. Sometimes it may help to change the medication used in treatment. In this review, we have looked at treatment with slow release oral morphine and levomethadone. These treatments are compared to the three medications used in Norway: buprenorphine with naloxone

Norwegian Institute of Public Health2017

114. Magnesium as an Alternative or Adjunct to Opioids for Chronic Pain: A Review of the Clinical Effectiveness and Guidelines

Magnesium as an Alternative or Adjunct to Opioids for Chronic Pain: A Review of the Clinical Effectiveness and Guidelines Magnesium as an Alternative or Adjunct to Opioids for Chronic Pain: A Review of the Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Magnesium as an Alternative or Adjunct to Opioids for Chronic Pain: A Review of the Clinical Effectiveness and Guidelines Magnesium as an Alternative or Adjunct to Opioids for Chronic Pain: A Review of the Clinical

Canadian Agency for Drugs and Technologies in Health - Rapid Review2017

116. Sustained Release Oral Morphine, Injectable Hydromorphone, and Prescription Diacetylmorphine for Opioid Use Disorder: Clinical and Cost-Effectiveness, and Guidelines

Sustained Release Oral Morphine, Injectable Hydromorphone, and Prescription Diacetylmorphine for Opioid Use Disorder: Clinical and Cost-Effectiveness, and Guidelines Sustained Release Oral Morphine, Injectable Hydromorphone, and Prescription Diacetylmorphine for Opioid Use Disorder: Clinical and Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Sustained Release Oral Morphine, Injectable Hydromorphone, and Prescription Diacetylmorphine for Opioid Use Disorder: Clinical (...) and Cost-Effectiveness, and Guidelines Sustained Release Oral Morphine, Injectable Hydromorphone, and Prescription Diacetylmorphine for Opioid Use Disorder: Clinical and Cost-Effectiveness, and Guidelines Published on: April 13, 2017 Project Number: RB1083-000 Product Line: Research Type: Drugs Report Type: Summary of Abstracts Result type: Report Question What is the comparative clinical effectiveness of sustained release oral morphine (SROM) versus standard of care (i.e., methadone or buprenorphine

Canadian Agency for Drugs and Technologies in Health - Rapid Review2017

117. Strategies for the Reduction or Discontinuation of Opioids: Guidelines

Strategies for the Reduction or Discontinuation of Opioids: Guidelines Strategies for the Reduction or Discontinuation of Opioids: Guidelines | CADTH.ca Find the information you need Strategies for the Reduction or Discontinuation of Opioids: Guidelines Strategies for the Reduction or Discontinuation of Opioids: Guidelines Published on: April 5, 2017 Project Number: RB1078-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What (...) are the evidence-based guidelines regarding tapering strategies for the reduction or discontinuation of opioids? What are the evidence-based guidelines regarding switching or crossover strategies for the reduction or discontinuation of opioids? Key Message Six evidence-based guidelines were identified regarding tapering, rotating, switching, or crossover strategies for the reduction or discontinuation of opioids. Tags analgesics, opioid, drug substitution, opioid-related disorders, other miscellaneous topics

Canadian Agency for Drugs and Technologies in Health - Rapid Review2017

118. How Would You Manage Opioid Use in These Three Patients?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center.

How Would You Manage Opioid Use in These Three Patients?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. The increase in overdose deaths from prescription opioids and heroin in the United States over the past 20 years is believed to have resulted from increases in prescription of opioids for management of acute and chronic pain. Managing chronic pain is challenging for primary care clinicians for many reasons, including the lack of evidence to guide practice. The Centers (...) for Disease Control and Prevention published a comprehensive guideline in 2016 to help clinicians with opioid prescribing for chronic pain. In this Grand Rounds, the guideline is reviewed and an expert discusses its application to 3 patients prescribed opioids to treat chronic pain.

Annals of Internal Medicine2017

119. Nonopioid, Over-the-Counter Analgesics Can Be as or More Effective Than Prescription Medications Containing Opioids in the Pain Management of Post-Extraction Patients

Nonopioid, Over-the-Counter Analgesics Can Be as or More Effective Than Prescription Medications Containing Opioids in the Pain Management of Post-Extraction Patients UTCAT3212, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Nonopioid, Over-the-Counter Analgesics Can Be as or More Effective Than Prescription Medications Containing Opioids in the Pain Management of Post-Extraction Patients Clinical Question For a post (...) -extraction patient, are over-the-counter pain medications as effective in pain relief as opioids? Clinical Bottom Line Non-opioid, over-the-counter analgesics can be as, or more, effective than prescription pain medications containing opioids. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Daniels/2011 678 Extraction patients with impacted third molars Randomized Controlled Trial Key results “1 or 2 tablets

UTHSCSA Dental School CAT Library2017

120. Opioids Used in Conjunction With Benzodiazepines Produce Worse Outcomes in Patients Experiencing Chronic Pain Compared To Sole Opioid Use

Opioids Used in Conjunction With Benzodiazepines Produce Worse Outcomes in Patients Experiencing Chronic Pain Compared To Sole Opioid Use UTCAT3169, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Opioids Used in Conjunction With Benzodiazepines Produce Worse Outcomes in Patients Experiencing Chronic Pain Compared To Sole Opioid Use Clinical Question For a patient experiencing chronic pain, will the use (...) of benzodiazepines with opioids, compared to opioids alone, produce better outcomes? Clinical Bottom Line For patients with chronic pain, the use of opioids in conjunction with benzodiazepines produces worse outcomes than opioids alone. This is supported by a cross-sectional study where it was noted that the combination of opioids and benzodiazepines correlated with poor mood and decreased patient function. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient

UTHSCSA Dental School CAT Library2017